Rationale: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1g (TIF1g) antibody. We report a case of anti-TIF1g antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor.
Introduction
Dermatomyositis (DM) is an idiopathic inflammatory myopathy, characterized by proximal skeletal muscle weakness, and specific cutaneous manifestations. High prevalence of malignant diseases in patients with inflammatory myopathy has been well recognized. [1] [2] [3] DM is diagnosed based on the classification criteria of Bohan and Peter. It includes clinical examinations such as myogenic enzymes, electromyography, and muscle biopsy in addition to clinical manifestations. [4, 5] Recently a number of myositis-specific autoantibodies related with clinical characteristics of DM have been reported. [6] Among them, antitranscription intermediary factor 1g (TIF1g) antibody is more prevalent in DM patients with malignancy than those without. [7, 8] Thymic tumors including thymoma and thymic carcinoma are diagnosed by histology. Thymic carcinomas show cytologic atypia, invasive margins, and loss of an organotypic appearance. [9] We report a case of anti-TIF1g antibody positive DM associated with thymic carcinoma which radiographically mimicked a benign tumor.
Case report
A 72-year-old Japanese man presented with painful skin rashes on knuckles and eyelids. His medical history was notable for a 15-year history of diabetes mellitus and a stroke 5 years ago. His family history was unremarkable. Three months after his first visit, an elevated serum level of creatine kinase (CK) was detected in outpatient clinic and he was admitted to a nearby hospital. On physical examination, the following were noted: proximal muscle weakness, heliotrope rash of the eyelids, erythematous rashes on elbows, shoulders, and right thigh, and Gottron's sign over his knuckles ( Fig. 1) . Laboratory tests showed elevated serum levels of CK (1576 IU/L) and aldolase (8.2 U/L), and the antinuclear antibody was positive (1:1280, speckled and nucleolar pattern). He was diagnosed with DM and was referred to our hospital for further investigation and treatment. While autoantibodies including anti-aminoacyl tRNA synthetase antibody, anti-Mi-2 antibody, and anti-melanoma differentiation-associated gene 5 antibodies were negative, anti-TIF1g antibody was positive (107 indexes). Magnetic resonance images showed high-intensity areas on whole-body muscles with short-tau inversion recovery images, suggesting the presence of muscular inflammation. A skin biopsy specimen revealed mononuclear cell infiltrations around vessels at the dermal-epidermal interface. The result of electromyogram of the proximal muscles was compatible with inflammatory myopathy.
Computed tomography (CT) scans showed an anterior mediastinal mass with diameter of 23 mm. It had homogenous density with little contrast effect and well-defined borders (Fig. 2) , leading to the radiographic diagnosis as non-invasive thymoma or thymic cyst. Knowing that anti-TIF1g antibody has been related to malignancies in DM patients, we performed thoracoscopic thymectomy to further confirm the diagnosis. Based on the 
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Medicine histologic findings, this tumor was ultimately diagnosed as squamous cell carcinoma of the thymus. Two weeks after the surgery, oral glucocorticoid (1.0 mg/kg/day) was administered followed by immediate disappearance of his skin involvement and by gradual improvement in muscle weakness. Under lowdose glucocorticoid maintenance, there is no feature of disease relapse at least for 1 year.
Discussion
The prevalence of malignancy in patients with DM has been estimated approximately 30%. [2, 10, 11] A type and site of cancers occurring in DM patients are mostly comparable in the general population. [10, 12] Although DM are usually treated with combination of glucocorticoid and immunosuppressive agents, some cases of paraneoplastic DM achieved remission without such treatment after the cure of underlying malignancy. [13] In our case, however, immunosuppressive treatment was needed, indicating that paraneoplastic immune response had been established and did not need sustained antigen presentation from cancer cells. Anti-TIF1g antibody is identified in about 20% of adult DM patients. [6, 14, 15] Among them, 60% to 80% have malignant diseases. [12] Despite such strong correlation between anti-TIF1g antibody, malignancy, and myositis, the pathogenesis of the interaction between them remains unclear. TIF1g has been known as a tumor suppressor by preventing TGF-b pathway, [16, 17] while overexpression of TIF1g has been reported to be associated with oncogenesis and poor prognosis in some cancers. [18, 19] It has been hypothesized that mutations of TIF1g genes in tumors provoke a specific antitumoral immune response which secondarily causes a crossreactivity to the target organs of myositis, including muscle, and skin. [12] The occurrence of thymic carcinoma is extremely rare in DM [20] and, vice versa, the incidence of paraneoplastic syndrome with thymic carcinoma is very low. [20, 21] The prognosis of thymic carcinoma is, however, obviously poorer compared with that of thymoma. Surgery should be considered in the management of thymic carcinoma. Complete resection is extremely important, and delay of diagnosis would result in poor outcome. [22] In addition, the diagnostic accuracy of radiography for thymic tumors is advanced but still has limitation to some extent. [23] In our case combined assessment using anti-TIF1g antibody and conventional screening for malignancy, although the latter had failed to present malignant aspect, ultimately lead to curative treatment. Anti-TIF1g antibody played a role as "autoimmune tumor marker" in the management of our patient.
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